HIV and AIDS
The Challenge
After more than two decades of progress, a future free of AIDS is within reach. Efforts by communities, governments, civil society, the private sector and global health partners have resulted in extraordinary progress in the fight against HIV. Globally, new HIV infections have declined by 42%, from 2.1 million in 2010 to 1.2 million in 2025.
But HIV remains a major infectious disease and a significant threat to global health security. In 2025, there were 1.2 million new infections globally and 570,000 people died of AIDS-related causes – deaths that are largely preventable.
Adolescent girls and young women (aged 15-24 years) continue to be at high risk of HIV infection in East and Southern Africa and are much more likely to acquire HIV compared to adolescent boys and young men.
Key populations – including men who have sex with men, trans and gender-diverse people, sex workers, people who use and/or inject drugs, and people in prison and other closed settings, and their sexual partners – accounted for an estimated two thirds% of new HIV infections outside sub-Saharan Africa and around 26% in sub-Saharan Africa in 2024.
There were 93,000 new infections globally among children in 2025 and only 55% of the 1.3 million children living with HIV were on treatment – far below adult coverage rates.
Funding cuts, humanitarian crises and barriers in accessing healthcare have slowed progress and heightened risks for the most vulnerable people. Global progress hinges on bold investment, the leadership of governments, the private sector, civil society and communities, and a shared commitment to lasting impact.
HIV and AIDS in Countries Where the Global Fund Invests
Funding
- The Global Fund provides 28% of all international financing for HIV programs.
- We have invested US$28.5 billion in programs to prevent and treat HIV and AIDS as of June 2026.
- We have invested US$9.6 billion in TB/HIV programs as of June 2026.
Prevention
- 10 million people were reached with HIV prevention services in 2025.
- 623,000 pregnant women living with HIV received medicine to keep them alive and prevent transmitting HIV to their babies in 2025.
Testing and Treatment
- In 2025, 87% of people living with HIV knew their status, 80% were accessing treatment and 74% were virally suppressed.
- 26.9 million people were on antiretroviral therapy for HIV in 2025.
- 12.1 million HIV tests were taken by key and priority populations.
Our Response
The Global Fund provides 28% of all international financing for HIV programs. We have invested US$28.5 billion in programs to prevent and treat HIV and AIDS and US$9.6 billion in TB/HIV programs as of June 2026.
Our investments in the fight against HIV are having an impact. As of 2025, in countries where the Global Fund invests, AIDS-related deaths have been reduced by 77% and new infections have been reduced by 64% since 2002.
Trends in AIDS-related deaths
Trends in new HIV infections
HIV burden estimates from UNAIDS, 2025 release. Estimation of “no prevention or ARVs” trends from Goals and AIM models where available. For some countries estimates of burden are not available from UNAIDS. Global Fund portfolio indicates countries that have recently received Global Fund HIV and AIDS funding and have reported programmatic results over the past two cycles. Global Fund Regional Groupings.
Treatment, Care and Support
Working with partners, we are making significant progress toward reaching WHO’s “treat all” guidance and the UNAIDS “95-95-95” targets. Those efforts have significantly increased the number of people living with HIV who know their HIV status, the number of people who know their status on antiretroviral therapy and the number of people on antiretroviral therapy who have a suppressed viral load (when the amount of HIV in a person’s blood becomes so low that it is undetectable and untransmissible).
In 2025, 26.9 million people were on antiretroviral therapy for HIV in countries where the Global Fund invests. This is up from 17.5 million people in 2017, but still far from the UNAIDS 95–95–95 target of 34 million people for 2025.
We also support multi-month (three months or more of medicine or prevention products at a time) and community dispensing of HIV prevention, care and treatment products, as well as community programs for antiretroviral therapy delivery, adherence support, community leadership, engagement and treatment literacy.
Prevention
The Global Fund invests in high-impact HIV prevention interventions such as condoms and lubricants, pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and harm reduction programs for people who inject drugs. In 2025, 1.1 million people received antiretroviral PrEP.
As well as these investments, we support countries to focus their efforts on locations with high HIV transmission and on people with the greatest HIV prevention needs – key populations and adolescent girls and young women, and their male sexual partners – so they have the tools, knowledge and power to prevent themselves from acquiring HIV.
We also work with partners to make HIV prevention options more accessible in spaces where people need rapid access to them. By investing in community-led monitoring, we support communities affected by HIV to monitor the accessibility, quality, acceptability and affordability of health services, so that these services are integrated and centered around the people who use them.
Market Shaping
The Global Fund is working with partners to accelerate equitable access to new or improved products for HIV prevention, testing, care and treatment. Through our market-shaping efforts, the Global Fund has been able to generate significant cost-savings for quality-assured HIV products, including drugs and products for prevention, testing, care and treatment.
For HIV prevention, market-shaping approaches have included condoms and lubricants, products for harm reduction programs and new PrEP options, and investments to ensure last-mile supply of these tools to the people who need them.
We are also working to expand access to quality-assured, low-cost HIV rapid diagnostic tests, including self-tests, and to support countries to introduce and scale up access to the most effective HIV treatment regimens. We have also supported countries in scaling up child-friendly HIV treatments.
One area of significant progress has been in the procurement of antiretrovirals for HIV treatment. In 2000, a one-year supply of HIV treatment for one person cost more than US$10,000. By 2018 this cost had been cut to US$75, and today it is as low as US$35.
In July 2025, the Global Fund signed an access agreement with Gilead Sciences to procure lenacapavir, a long-acting injectable for HIV prevention, for low- and middle-income countries. This marked the first time in history that an HIV prevention product was introduced in low- and middle-income countries at the same time as in high-income countries – a significant milestone for global health equity.
By June 2026, all nine early-adopter countries in Africa supported by the Global Fund had launched lenacapavir. By mid-August 2026, nearly 100,000 people had received it. By the end of 2026, a total of 24 countries worldwide are expected to receive lenacapavir with support from the Global Fund, the United States and other partners. Combined with other prevention innovations in the pipeline, such as alimatravir, the once-monthly oral PrEP, lenacapavir offers the potential to achieve a dramatic reduction in new HIV infections, accelerating the end of AIDS.
We have continued to prioritize investments in HIV prevention for adolescent girls and young women, focusing on 12 priority countries – Botswana, Eswatini, Kenya, Lesotho, Malawi, Mozambique, Namibia, Uganda, South Africa, Tanzania, Zambia and Zimbabwe – where HIV transmission for young women is very high.
The investments in these 12 countries have contributed to a 75% reduction in the HIV incidence rate among women aged 15-24 between 2010 and 2025.
One crucial strategy in the battle against HIV is preventing transmission from pregnant women to their babies. In 2025 in the countries where we invest, 90% of the pregnant women living with HIV received treatment to keep themselves healthy and prevent transmission to their babies, compared to only 50% in 2010.
Read the Latest Results Report
Learn More